Zacks Research Forecasts Lower Earnings for Cardiff Oncology

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Equities researchers at Zacks Research cut their FY2027 earnings per share (EPS) estimates for Cardiff Oncology in a research note issued to investors on Monday, June 22nd. Zacks Research analyst J. Vandermosten now forecasts that the company will earn ($0.80) per share for the year, down from their previous forecast of ($0.76). The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.66) per share. Zacks Research also issued estimates for Cardiff Oncology’s FY2028 earnings at ($0.79) EPS.

Cardiff Oncology (NASDAQ:CRDF) last released its earnings results on Thursday, May 14th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Cardiff Oncology had a negative net margin of 8,527.43% and a negative return on equity of 95.51%. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.09 million.

Other equities research analysts have also recently issued reports about the stock. Craig Hallum cut shares of Cardiff Oncology from a “buy” rating to a “hold” rating and set a $2.00 price objective for the company. in a research report on Wednesday, June 3rd. TD Cowen lowered shares of Cardiff Oncology from a “buy” rating to a “hold” rating in a report on Monday, June 1st. Piper Sandler cut their price target on shares of Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Wall Street Zen downgraded Cardiff Oncology from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, HC Wainwright lowered Cardiff Oncology from a “buy” rating to a “neutral” rating in a research report on Monday, June 1st. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $9.80.

Cardiff Oncology Stock Performance

Shares of NASDAQ CRDF opened at $1.26 on Wednesday. The company’s 50 day moving average price is $1.61 and its 200-day moving average price is $1.96. Cardiff Oncology has a 52-week low of $1.16 and a 52-week high of $4.55. The company has a market capitalization of $86.15 million, a P/E ratio of -1.88 and a beta of 1.36.

Institutional Investors Weigh In On Cardiff Oncology

A number of large investors have recently bought and sold shares of CRDF. Capital Advisors Wealth Management LLC bought a new stake in Cardiff Oncology in the fourth quarter valued at $30,000. Tamar Securities LLC bought a new position in shares of Cardiff Oncology during the 4th quarter worth about $32,000. Brooklyn Investment Group acquired a new stake in shares of Cardiff Oncology in the 3rd quarter valued at about $26,000. R Squared Ltd acquired a new stake in shares of Cardiff Oncology in the 4th quarter valued at about $36,000. Finally, Engineers Gate Manager LP bought a new stake in Cardiff Oncology in the 2nd quarter valued at about $43,000. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Gary W. Pace acquired 30,000 shares of Cardiff Oncology stock in a transaction dated Thursday, June 18th. The stock was bought at an average price of $1.22 per share, with a total value of $36,600.00. Following the transaction, the director directly owned 1,356,376 shares in the company, valued at $1,654,778.72. This represents a 2.26% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Mani Mohindru acquired 24,703 shares of the stock in a transaction dated Thursday, June 18th. The stock was bought at an average price of $1.21 per share, with a total value of $29,890.63. Following the purchase, the chief executive officer directly owned 24,703 shares in the company, valued at $29,890.63. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 8.50% of the stock is currently owned by corporate insiders.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.